Publication | Closed Access

A phase I clinical and pharmacokinetic study of the camptothecin glycoconjugate, BAY 38-3441, as a daily infusion in patients with advanced solid tumors

OncologyBay 38-3441MedicineDaily InfusionPharmacotherapyAnti-cancer AgentCancer TreatmentCamptothecin GlycoconjugatePharmacologyRadiation OncologyCancer Research